The therapeutic and pharmacological potential of cannabidiol

Authors

DOI:

https://doi.org/10.33448/rsd-v9i11.9686

Keywords:

Cannabinoids; Cannabidiol; Pharmacotherapy; Toxicology.

Abstract

The article reviews the therapeutic and pharmacological effects of cannabidiol, characterizing possible adverse and toxicological effects. This is an integrative bibliographic review carried out in the databases of PubMed, Science Direct and LILACS with the descriptors “drug effects”, “canabidiol” and “treatment” in english, using the Boolean operator AND and restricted to the years 2015 to July 2020. 89 articles were initially found, from the application of the inclusion criteria, it was possible to select the 27 articles constituting the work, from which information about authors, objective, sample, type of research, dosage and result for the composition of results table were obtained. It can be concluded that cannabidiol has therapeutic effects in pathologies related to the central nervous system and the immune system, places where it has mechanisms of action and that intoxication events are not frequently reported, however it has a vast report of adverse effects, in mostly light such as drowsiness and gastric discomfort.

References

Alalawi, A., Dodu, J. C., Woolley-Roberts, M., Brodie, J., Di Marzo, V., & Soderstrom, K. (2019). Cannabidiol improves vocal learning-dependent recovery from, and reduces magnitude of deficits following, damage to a cortical-like brain region in a songbird pre-clinical animal model. Neuropharmacology, 158.

Barnett, J. R., Grinspoon, R. A., Harisinghani, M., Caruso, P. A., Thiele, & E. A. (2020). The efficacy of cannabidiol on renal angiomyolipoma and subependymal giant cell tumor volume in tuberous sclerosis complex. Journal of Clinical Neuroscience, 77, 85–88.

Botelho, L. L. R., Cunha, C. C. de. A., & Macedo, M. (2011). O MÉTODO DA REVISÃO INTEGRATIVA NOS ESTUDOS ORGANIZACIONAIS. Revista Eletrônica Gestão e Sociedade, 5(11), 121-136.

Callejas, G. H., Figueira, R. L., Gonçalves, F. L. L., Zuardi, A. W., Crippa, J. A., Hallak, J. E., & Sbragia, L. (2018) Maternal administration of cannabidiol promotes an anti-inflammatory effect on the intestinal wall in a gastrochisis rat model. Brazilian Journal of Medical and Biological Research, 51(5), 1-9.

Campos, A. C., Brant, F., Miranda, A. S., Machado, F. S., & Teixeira, A. L. (2015). Cannabidiol increases survival and promotes rescue of cognitive function in a murine model of cerebral malaria. Neuroscience, 289, 166–180.

Cuñetti, L., Manzo, L., Peyraube, R., Arnaiz, J., Curi, L., & Orihuela, S. (2018). Chronic Pain Treatment With Cannabidiol in Kidney Transplant Patients in Uruguay. Transplantation Proceedings, 50(2), 461–464.

Carlos, D. M., Campeiz, A. B., Silva, J. L. da., Fernandes, M. I. D., Leitão, M. N. da. C., Silva, M. A. I., & Ferriani, M. das. G. C. (2017). Intervenções na escola para prevenção da violência nas relações de intimidade entre adolescentes: revisão integrativa da literatura. Revista de Enfermagem Referência, IV(14), 133-146.

Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018). Translational Ivestigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age. Frontiers in Immunology, 09, 1-16.

Devinsky, O., Verducci, C., Thiele, E. A., Laux, L. C., Patel, A. D., Filloux, F., Szaflarski, J. P., Wilfong, A., Clark, G. D., Park, Y. D., Seltzer, L. E., Bebin, E. M., Flamini, R., Wechsler, R. T., & Friedman, D. (2018). Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy and Behavior, 86, 131–137.

Ebrahimi-Fakhari, D., Agricola, K. D., Tudor, C., Krueger, D., & Franz, D. N. (2020). Cannabidiol Elevates Mechanistic Target of Rapamycin Inhibitor Levels in Patients With Tuberous Sclerosis Complex. Pediatric Neurology, 105, 59–61.

Elsaid, S., Kloiber, S., & Le Foll, B. (2019). Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings. Progress in Molecular Biology and Translational Science, 167, 25-75.

Gobira, P. H., Vilela, L. R., Gonçalves, B. D. C., Santos, R. P. M., de Oliveira, A. C., Vieira, L. B., Aguiar, D. C., Crippa, J. A., & Moreira, F. A. (2015). Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release. NeuroToxicology, 50, 116–121.

Herlopian, A., Hess, E. J., Barnett, J., Geffrey, A. L., Pollack, S. F., Skirvin, L., Bruno, P., Sourbron, J., & Thiele, E. A. (2020). Cannabidiol in treatment of refractory epileptic spasms: An open-label study. Epilepsy and Behavior, 106.

Jensen, H. M., Korbut, R., Kania, P. W., & Buchmann, K. (2018). Cannabidiol effects on behaviour and immune gene expression in zebrafish (Danio rerio). PLoS ONE, 13(7).

Jeong, S., Yun, H. K., Jeong, Y. A., Jo, M. J., Kang, S. H., Kim, J. L., Kim, D. Y., Park, S. H., Kim, B. R., Na, Y. J., Lee, S. Il, Kim, H. Do, Kim, D. H., Oh, S. C., & Lee, D. H. (2019). Cannabidiol-induced apoptosis is mediated by activation of Noxa in human colorectal cancer cells. Cancer Letters, 447, 12–23.

Kaplan, E. H., Offermann, E. A., Sievers, J. W., & Comi, A. M. (2017). Cannabidiol Treatment for Refractory Seizures in Sturge-Weber Syndrome. Pediatric Neurology, 71, 18-23.

Kosgodage, U. S., Uysal-Onganer, P., MacLatchy, A., Mould, R., Nunn, A. V., Guy, G. W., Kraev, I., Chatterton, N. P., Thomas, E. L., Inal, J. M., Bell, J. D., & Lange, S. (2019). Cannabidiol Affects Extracellular Vesicle Release, miR21 and miR126, and Reduces Prohibitin Protein in Glioblastoma Multiforme Cells. Translational Oncology, 12(3), 513–522.

Linge, R., Jiménez-Sánchez, L., Campa, L., Pilar-Cuéllar, F., Vidal, R., Pazos, A., Adell, A., & Díaz, Á. (2016). Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: Role of 5-HT1A receptors. Neuropharmacology, 103, 16–26.

Luján, M. Á., Castro-Zavala, A., Alegre-Zurano, L., & Valverde, O. (2018). Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus. Neuropharmacology, 143, 163–175.

López, G. E. Á., Brindis, F., Niizawa, S. C., & Martínez, R. V. (2014). Cannabis sativa L., uma planta singular. Revista Mexicana de Ciências Farmacéuticas, 45(4).

Matos, R. L. A., Spinola, L. A., Barboza, L. L., Garcia, D. R., França, T. C. C., & Affonso, R. S. (2017). O uso do canabidiol no tratamento da epilepsia. Revista Virtual de Química, 9(2).

Mechoulam, R. (2010). Endocanabinoides e transtornos psiquiátricos: a estrada á frente. Revista Brasileira de Psiquiatria, 32(Suppl. 1), 5-6.

Mendes, K. D. S., Silveira, R. C. C. P., & Galvão, C. M. (2008) Revisão Integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto – Enfermagem, 17(4), 758-764.

Mitelpunkt, A., Kramer, U., Hausman Kedem, M., Zilbershot Fink, E., Orbach, R., Chernuha, V., Fattal-Valevski, A., Deutsch, L., Heffetz, D., & Sacks, H. (2019). The safety, tolerability, and effectiveness of PTL-101, an oral cannabidiol formulation, in pediatric intractable epilepsy: A phase II, open-label, single-center study. Epilepsy and Behavior, 98, 233–237.

Naranjo, C. J., Osborne, A. L., & Weston-Green, K. (2019). Effect of cannabidiol on muscarinic neurotransmission in the pre-frontal cortex and hippocampus of the poly I:C rat model of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 94.

Nascimento, G. C. do, Ferrari, D. P., Guimaraes, F. S., Del Bel, E. A., Bortolanza, M., & Ferreira- Junior, N. C. (2020). Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson’s disease. Neuropharmacology, 163.

Nascimento, P. A., Schultz, J., Gonzalez, M. H., & Oliveira, A. (2020). Simple GFAAS Method for determination of Pb, As and Cd in Cannabidiol Extracts used for therapeutic purposes. Journal of the Bazilian Chemical Society, 31(5), 894-903.

Neubauer, D., Perković Benedik, M., & Osredkar, D. (2018). Cannabidiol for treatment of refractory childhood epilepsies: Experience from a single tertiary epilepsy center in Slovenia. Epilepsy and Behavior, 81, 79–85.

Osborne, A. L., Solowij, N., Babic, I., Lum, J. S., Huang, X. F., Newell, K. A., & Weston-Green, K. (2019). Cannabidiol improves behavioural and neurochemical deficits in adult female offspring of the maternal immune activation (poly I:C) model of neurodevelopmental disorders. Brain, Behavior, and Immunity, 81, 574–587.

Osborne, A. L., Solowij, N., Babic, I., Lum, J. S., Newell, K. A., Huang, X. F., & Weston-Green, K. (2019). Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 95.

Palmieri, B., Laurino, C., & Vadalà, M. (2017). Short-term efficacy of CBD-enriched hemp oil in girls with dysautonomic syndrome after human papillomavirus vaccination. Israel Medical Association Journal, 19(2), 79–84.

Porcari, G. S., Fu, C., Doll, E. D., Carter, E. G., & Carson, R. P. (2018). Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. Epilepsy and Behavior, 80, 240–246.

Rahimi, A., Faizi, M., Talebi, F., Noorbakhsh, F., Kahrizi, F., & Naderi, N. (2015). Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice. Neuroscience, 290, 279–287.

Sales, A. J., Guimarães, F. S., & Joca, S. R. L. (2020). CBD modulates DNA methylation in the pré-frontal córtex and hippocampus of mice exposed to force swim. Behaviour Brain Research, 388.

Santos, R. G. dos., Guimarães, F. S., Crippa, J. A. S., Hallak, J. E. C., Rossi, G. N., Rocha, J. M., & Zuardi, A. W. (2020) Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opinion on Drug Metabolism & Toxicology, 16(6), 517-526.

Sonego, A. B., Gomes, F. V., Del Bel, E. A., & Guimaraes, F. S. (2016). Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice. Behavioural Brain Research, 309, 22–28.

Souza, M. T., Silva, M. D. da., & Carvalho, R. de. (2010). Revisão integrativa: o que é e como fazer. Einstein, 8(1 Part 1), 102-106.

Tzadok, M., Uliel-Siboni, S., Linder, I., Kramer, U., Epstein, O., Menascu, S., Nissenkorn, A., Yosef, O. B., Hyman, E., Granot, D., Dor, M., Lerman-Sagie, T., & Ben-Zeev, B. (2016). CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. Seizure, 35, 41–44.

Xu, C., Chang, T., Du, Y., Yu, C., Tan, X., & Li, X. (2019). Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model. Environmental Toxicology and Pharmacology, 70.

Youssef, F. F., & Irving, A. J. (2012). From Cannabis to the Endocannabinoid System: Refocusing Attention on Potencial Clinical Benefits. West Indian Medical Journal, 61(3), 264-270.

Published

11/11/2020

How to Cite

Silva, L. M. G. da ., Alencar, R. A. de ., & Gomes Júnior, A. L. (2020). The therapeutic and pharmacological potential of cannabidiol. Research, Society and Development, 9(11), e2019119686. https://doi.org/10.33448/rsd-v9i11.9686

Issue

Section

Health Sciences